FDA approved gene tx for children w/ early-onset MLD + 13 updates...👇
Optinose
🎯 FDA approved XHANCE, the first and only medication treating adults with chronic rhinosinusitis w/o nasal polyps.
Orchard Therapeutics
🎯 Received FDA approval for Lenmeldy™ (atidarsagene autotemcel) treating children w/ early-onset metachromatic leukodystrophy.
Bristol Myers Squibb
🎯 EU approved Abecma (idecabtagene vicleucel), the first CAR-T cell therapy for triple-class exposed r/r multiple myeloma.
Journey Medical Corporation
🎯 FDA accepted the NDA for treating rosacea w/ PDUFA goal date of Nov. 4, 2024.
Citius Pharmaceuticals
🎯 FDA accepted the BLA resubmission of LYMPHIR™ (Denileukin Diftitox) for treating r/r CTCL.
Seelos Therapeutics
🔬 Reported top-line data for SLS-005 (IV Trehalose) treating ALS.
AstraZeneca
🔬 Lynparza and Imfinzi showed more than doubled median duration of response vs. chemotherapy in endometrial cancer.
Kiromic BioPharma
🔬 Reported tumor stabilization and complete disappearance of brain metastases in the early efficacy datasets from the Deltacel-01 trial of Deltacel™ (KB-GDT-01).
Crinetics
🔬 Oral Paltusotine achieved both primary and secondary endpoints in the Ph3 PATHFNDR-2 study in acromegaly patients.
Gilead Sciences & CymaBay
🤝 Gilead completed the acquisition of CymaBay.
Fusion Pharmaceuticals
🤝 AZN To acquire Fusion Pharmaceuticals expanding its radioconjugates pipeline treating cancer.
Novartis & MorphoSys
🤝 U.S. Antitrust cleared the proposed acquisition of MorphoSys.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
March 18-22, 2024
Article History:
RF, DV (03/22/24)
Comentários